Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Boehringer Ingelheim
Express Scripts
AstraZeneca
Johnson and Johnson

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022184

See Plans and Pricing

« Back to Dashboard

NDA 022184 describes LUMIGAN, which is a drug marketed by Allergan and is included in two NDAs. It is available from one supplier. There are twelve patents protecting this drug and two Paragraph IV challenges. Additional details are available on the LUMIGAN profile page.

The generic ingredient in LUMIGAN is bimatoprost. There are twelve drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
Summary for 022184
Tradename:LUMIGAN
Applicant:Allergan
Ingredient:bimatoprost
Patents:12
Pharmacology for NDA: 022184
Medical Subject Heading (MeSH) Categories for 022184
Suppliers and Packaging for NDA: 022184
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184 NDA Allergan, Inc. 0023-3205 0023-3205-02 1 BOTTLE, DROPPER in 1 CARTON (0023-3205-02) > 2.5 mL in 1 BOTTLE, DROPPER
LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184 NDA Allergan, Inc. 0023-3205 0023-3205-03 1 BOTTLE, DROPPER in 1 CARTON (0023-3205-03) > 2.5 mL in 1 BOTTLE, DROPPER
Paragraph IV (Patent) Challenges for 022184
Tradename Dosage Ingredient NDA Submissiondate
LUMIGAN SOLUTION/DROPS;OPHTHALMIC bimatoprost 022184 2011-04-05

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION/DROPS;OPHTHALMICStrength0.01%
Approval Date:Aug 31, 2010TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Jun 13, 2027Product Flag?YSubstance Flag?YDelist Request?
Patent:  Start TrialPatent Expiration:Mar 16, 2025Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Mar 16, 2025Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION

Expired US Patents for NDA 022184

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010   Start Trial   Start Trial
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010   Start Trial   Start Trial
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKinsey
McKesson
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.